Article
Immunology
Zhuwan Lyu, Bingyuan Huang, Jun Zhang, Qiwei Qian, Xiting Pu, Nana Cui, Yiyan Ou, Bo Li, Zhengrui You, Min Lian, Ruqi Tang, Weihua Chen, Zhicong Zhao, Jiajie Hou, M. Eric Gershwin, Haiyan Zhang, Qiang Xia, Xiong Ma
Summary: This study reveals the critical role of N6-methyladenosine (m6A) reader YTHDF2 in myeloid-derived suppressor cells (MDSC) and its impact on autoimmune hepatitis (AIH). The loss of YTHDF2 leads to increased MDSCs, particularly PMN-MDSCs, in the liver and bone marrow. YTHDF2 deficiency attenuates concanavalin (ConA)-induced liver injury by promoting MDSC expansion and chemotaxis. Additionally, YTHDF2 upregulation is observed in the livers of AIH patients.
JOURNAL OF AUTOIMMUNITY
(2023)
Article
Immunology
Jiajun Chen, Shiqi Cai, Renjie Li, Jie Xie, Fan Yang, Tao Liu
Summary: This study found that MDSCs play an important role in sepsis-induced immune dysfunction. Inhibiting COX-2 may be a promising therapy for MDSCs-induced immunosuppression.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Immunology
Samantha L. Tucker, Demba Sarr, Balazs Rada
Summary: Cystic Fibrosis is a genetic disease that causes chronic lung inflammation and infections, leading to high mortality rates. Immune system disruption in CF results in impaired immune responses, chronic infections with pathogens, and alterations in T cell and neutrophil functions. The role of P. aeruginosa and gMDSCs in T cell suppression and immune evasion in CF remains a subject of ongoing research.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Hui Zhang, Qi-Wei Li, Yuan-Yuan Li, Xue Tang, Ling Gu, Han-Min Liu
Summary: Pulmonary hypertension (PH) is characterized by increased pulmonary vascular resistance and pressure, and the relationship between myeloid-derived suppressor cells (MDSCs) and PH has been studied. MDSCs are a group of cells that can suppress T-cell responses and potentially exacerbate the development of diseases. Understanding the relationship between MDSCs and PH can help identify potential therapeutic targets for the treatment of PH.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Ina N. Eckert, Eliana Ribechini, Katja J. Jarick, Sandra Strozniak, Sarah J. Potter, Andreas Beilhack, Manfred B. Lutz
Summary: The study discovered that the adhesion of VLA-1 integrin to collagen IV plays a critical role in extending the contact time between MDSCs and T cells, which is necessary for suppression.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Medicine, General & Internal
Iosif Papafragkos, Efrosyni Markaki, Christina Kalpadakis, Panayotis Verginis
Summary: Myeloid-derived suppressor cells (MDSCs) are potent regulators of the immune system, playing a role in cancer but their specific contribution to lymphomas remains unclear. This review focuses on MDSCs in lymphomas, discussing literature and lessons learned from animal models, and highlights future research directions and challenges in understanding the immune system complexities in malignancies.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Medicine, General & Internal
Suncica Kapor, Juan F. Santibanez
Summary: This review discusses the main features of MDSCs and MSCs in myeloid malignancies, revealing that MDSCs are elevated in numbers and exhibit strong immunosuppressive capabilities, while MSCs not only have immunosuppressive properties but also regulate the growth, apoptosis, and chemotherapy resistance of myeloid leukemia cells.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Immunology
Estefania Prochetto, Eliana Borgna, Carlos Jimenez-Cortegana, Victor Sanchez-Margalet, Gabriel Cabrera
Summary: Myeloid-derived suppressor cells (MDSCs) play a role in both pathological and non-pathological conditions, including cancer, infections, pregnancy, aging, and vaccination. Vaccination is a crucial public health measure, but the presence of MDSCs may impact vaccine efficacy.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Review
Cell Biology
Tianmiao Ma, Bernhard W. Renz, Matthias Ilmer, Dominik Koch, Yuhui Yang, Jens Werner, Alexandr V. Bazhin
Summary: Myeloid-derived suppressor cells (MDSCs) play a crucial role in the tumor microenvironment (TME) and have been linked to poor prognosis and drug resistance in cancer. Further research is needed to fully understand the definition and phenotypes of MDSCs in humans.
Article
Immunology
Priyanka Namdev, Shiv Patel, Brandi Sparling, Ankita Garg
Summary: The study found that monocytic myeloid-derived suppressor cells (MDSC) in fully suppressed HIV-infected individuals have lower anti-mycobacterial activity against Mycobacterium tuberculosis (Mtb) compared to healthy controls, with changes in Toll-like receptor and IL-27 signaling pathways. Neutralizing IL-27 and overexpression of MyD88 synergistically controlled intracellular replication of Mtb in HIV MDSC, suggesting MDSC as novel mediators of tuberculosis in HIV-Mtb co-infected individuals with virologic suppression.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Taosan Li, Fang Zheng, Fanjun Cheng
Summary: This article analyzes the role of MDSCs in lymphopenia in COVID-19 patients and discusses their immunopathologic changes and potential therapeutic targets.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Chemistry, Multidisciplinary
Xinghang Dai, Long Ren, Mengxi Liu, Hao Cai, Hu Zhang, Qiyong Gong, Zhongwei Gu, Kui Luo
Summary: MDSCs have been explored as an important immunotherapeutic target in cancer immunology, and nanomedicines have shown potential in reversing immunosuppressive tumors into immunoresponsive ones to enhance therapeutic efficacy.
Review
Biochemistry & Molecular Biology
Jingshan Cai, Yudan Cui, Jun Yang, Shengjun Wang
Summary: MDSCs play a crucial role in tumor immunity, closely linked to tumor EMT and possessing unique functions in an immunosuppressive environment.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2021)
Article
Immunology
Jie Shen, Mengyu Zhang, Ke Zhang, Yahan Qin, Meifang Liu, Shujuan Liang, Daquan Chen, Meiyu Peng
Summary: This study found that Angelica polysaccharide (APS) promoted the proliferation, differentiation, and immunosuppressive function of myeloid-derived suppressor cells (MDSC) through the STAT1 and STAT3 signaling pathways. In vivo, APS increased the proportion of MDSC in mice, suggesting that its clinical application should consider the possible side effects of increasing MDSC quantity and function.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Yudan Cui, Jingshan Cai, Wenxin Wang, Shengjun Wang
Summary: HDACIs are antitumor drugs that enhance gene transcription via epigenetic regulation, with cytotoxic properties against tumor cells. The effects of HDACIs on immunocytes in the tumor microenvironment, specifically MDSCs, are still not fully understood.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Akaolisa Samuel Eziokwu, Leticia Varella, Megan Lynn Kruse, Xuefei Jia, Halle C. F. Moore, George Thomas Budd, Jame Abraham, Alberto J. Montero
Summary: The study evaluated the effectiveness of continuing CDK4/6 inhibitors beyond the first disease progression in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer, showing a median progression-free survival of approximately 12 months.
CLINICAL BREAST CANCER
(2021)
Article
Oncology
Veronica Mariotti, Hyo Han, Roohi Ismail-Khan, Shou Jiang Tang, Patrick Dillon, Alberto J. Montero, Andrew Poklepovic, Susan Melin, Nuhad K. Ibrahim, Eugene Kennedy, Nicholas Vahanian, Charles Link, Lucy Tennant, Shelly Schuster, Chris Smith, Oana Danciu, Paul Gilman, Hatem Soliman
Summary: In a prospective clinical trial, the addition of the IDO1 pathway inhibitor indoximod to a taxane did not improve progression-free survival in patients with ERBB2-negative metastatic breast cancer compared to a taxane alone. This study highlights the importance of exploring new treatment strategies for overcoming tumor immune suppression in breast cancer.
Editorial Material
Oncology
Stefano Ugel, Vincenzo Bronte
Summary: The study reveals a novel pathway regulating the interaction between M-MDSCs and cancerous plasma cells in multiple myeloma.
CANCER IMMUNOLOGY RESEARCH
(2021)
Article
Oncology
Lifen Cao, Robert Shenk, Nickolas Stabellini, Megan E. Miller, Christopher W. Towe, Alberto J. Montero
Summary: In this study comparing adjuvant chemo-HER2 therapy and HER2 monotherapy in patients with pT1N0 HER2+ BC, a modest survival advantage was associated with chemo-HER2 therapy.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Hanjie Mo, Catherine E. Renna, Halle C. F. Moore, Jame Abraham, Megan L. Kruse, Alberto J. Montero, Susan B. LeGrand, Lu Wang, G. Thomas Budd
Summary: This retrospective study found that patients who received everolimus + exemestane with prior CDK4/6 inhibitor use had a significantly decreased progression free survival. It is reasonable to use this combination after CDK4/6 inhibitors in selected patients.
CLINICAL BREAST CANCER
(2022)
Article
Health Care Sciences & Services
Askal Ayalew Ali, Rima Tawk, Hong Xiao, Anastasia Semykina, Alberto J. Montero, Richard K. Moussa, Olayiwola Popoola, Vakaramoko Diaby
Summary: The study found that combining radiotherapy with hormonal therapy is cost-effective for women aged 66 and older with hormone receptor positive early-stage breast cancer in the US.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
(2022)
Article
Oncology
Sara Magri, Beatrice Musca, Camilla Bonaudo, Ada Tushe, Maria Giovanna Russo, Elena Masetto, Vittorina Zagonel, Giuseppe Lombardi, Alessandro Della Puppa, Susanna Mandruzzato
Summary: Glioblastoma (GBM) is a highly aggressive type of brain cancer with a challenging treatment landscape due to the immunosuppressive tumor microenvironment. This study reveals differences in immune profiles in central and marginal tumor areas, emphasizing the importance of understanding how treatments impact the immune composition for recurrence prevention. Detecting immune landscape changes in GBM relapses can aid in better stratification and treatment approaches.
Editorial Material
Oncology
Priyanka M. Reddy, James M. Martin, Alberto J. Montero
JCO ONCOLOGY PRACTICE
(2022)
Article
Oncology
Lifen Cao, Christopher W. Towe, Robert Shenk, Nickolas Stabellini, Amanda L. Amin, Alberto J. Montero
Summary: In HER2+ breast cancer with tumor size <= 5 mm, the addition of adjuvant systemic therapy after surgical excision was not associated with improved overall survival (OS) compared with local therapy alone.
Letter
Clinical Neurology
Susanna Mandruzzato, Alessandro Della Puppa
WORLD NEUROSURGERY
(2022)
Letter
Oncology
Lifen Cao, Nickolas Stabellini, Amanda L. Amin, Alberto J. Montero
Article
Oncology
Francois-Clement Bidard, Virginia G. Kaklamani, Patrick Neven, Guillermo Streich, Alberto J. Montero, Frederic Forget, Marie-Ange Mouret-Reynier, Joo Hyuk Sohn, Donatienne Taylor, Kathleen K. Harnden, Hung Khong, Judit Kocsis, Florence Dalenc, Patrick M. Dillon, Sunil Babu, Simon Waters, Ines Deleu, Jose A. Garcia Saenz, Emilio Bria, Marina Cazzaniga, Janice Lu, Philippe Aftimos, Javier Cortes, Shubin Liu, Giulia Tonini, Dirk Laurent, Nassir Habboubi, Maureen G. Conlan, Aditya Bardia
Summary: Elacestrant, a novel oral selective estrogen receptor degrader, demonstrated significant improvement in progression-free survival in patients with pretreated estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer, including those with ESR1 mutations, with manageable adverse events.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Nickolas Stabellini, Benjamin Tomlinson, Jennifer Cullen, John Shanahan, Kristin Waite, Alberto J. J. Montero, Jill S. S. Barnholtz-Sloan, Nelson Hamerschlak
Summary: This study conducted a comprehensive analysis of sex differences in acute myeloid leukemia (AML) and found that there are disparities in incidence and survival between males and females. Treatment and healthcare factors have important implications for survival rates.
Article
Oncology
Nickolas Stabellini, Lifen Cao, Christopher W. Towe, Amanda L. Amin, Alberto J. Montero
Summary: This study demonstrates that in patients with HR+/HER2-node negative breast cancer, adjuvant chemotherapy plus endocrine therapy (CET) is associated with significantly higher overall survival (OS) compared to endocrine therapy alone (ET), especially in women over 50 years old with a recurrence score (RS) of 26 or higher.
Article
Oncology
Mohammadhadi Khorrami, Vidya Sakar Viswanathan, Priyanka Reddy, Nathaniel Braman, Siddharth Kunte, Amit Gupta, Jame Abraham, Alberto J. Montero, Anant Madabhushi
Summary: Imaging texture biomarkers before and after CDK4/6i therapy can predict early response and overall survival in MBC patients with liver metastases. Radiomic features can predict a lack of response earlier than standard anatomic/RECIST 1.1 assessment, highlighting the need for further study and clinical validation.
